Apolipoprotein A-I mimetic peptide 4f rescues pulmonary hypertension by inducing MicroRNA-193-3p

Circulation

Volumn 130, Issue 9, 2014, Pages 776-785

  Sharma, Salil ^a   Umar, Soban ^a   Potus, Francois ^d   Iorga, Andrea ^a   Wong, Gabriel ^a   Meriwether, David ^b   Breuils Bonnet, Sandra ^d   Mai, Denise ^a   Navab, Kaveh ^a,b   Ross, David ^c   Navab, Mohamad ^a,b   Provencher, Steeve ^d   Fogelman, Alan M ^b   Bonnet, Sébastien ^d   Reddy, Srinivasa T ^b,c   Eghbali, Mansoureh ^c  

^a Division of Molecular Medicine   (United States)

^b Division of Cardiology   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d LAVAL UNIVERSITY   (Canada)

Author keywords

Apolipoprotein A I mimetic peptide 4F; Human; Lipoproteins; MicroRNAs; MiR 193; Pulmonary arterial hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN A1 MIMETIC PEPTIDE 4F; HYDROXY FATTY ACID; HYDROXYICOSATETRAENOIC ACID; HYDROXYOCTADECADIENOIC ACID; LIPOXYGENASE; MICRORNA; MICRORNA 193; MONOCROTALINE; PEPTIDE; RETINOID X RECEPTOR ALPHA; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; LUNG HEMODYNAMICS; LUNG PARENCHYMA; LUNG STRUCTURE; LUNG WEIGHT; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY;

APOLIPOPROTEIN A-I MIMETIC PEPTIDE 4F; LIPOPROTEINS; MICRORNAS; MIR-193, HUMAN; PULMONARY ARTERIAL HYPERTENSION;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; HYPERTENSION, PULMONARY; MALE; MICE; MICE, INBRED C57BL; MICRORNAS; MUSCLE, SMOOTH, VASCULAR; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, IGF TYPE 1; RETINOID X RECEPTOR ALPHA;

EID: 84907376787     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.114.007405     Document Type: Article

References (54)

1. Umar S, Steendijk P, Ypey DL, Atsma DE, van der Wall EE, Schalij MJ, van der Laarse A. Novel approaches to treat experimental pulmonary arterial hypertension: a review. J Biomed Biotechnol. 2010; 2010: 702836.
2. Paulin R, Meloche J, Courboulin A, Lambert C, Haromy A, Courchesne A, Bonnet P, Provencher S, Michelakis ED, Bonnet S. Targeting cell motility in pulmonary arterial hypertension. Eur Respir J. 2014; 43: 531-544.
3. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest. 2008; 118: 2372-2379.
4. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fonarow GC, Vahabzadeh K, Hama S, Hough G, Kamranpour N, Berliner JA, Lusis AJ, Fogelman AM. The oxidation hypothesis of ath-erogenesis: the role of oxidized phospholipids and HDL. J Lipid Res. 2004; 45: 993-1007.
5. Staprans I, Rapp JH, Pan XM, Feingold KR. The effect of oxidized lipids in the diet on serum lipoprotein peroxides in control and diabetic rats. J Clin Invest. 1993; 92: 638-643.
6. Imaizumi S, Grijalva V, Navab M, Van Lenten BJ, Wagner AC, Anantharamiah GM, Fogelman AM, Reddy ST. L-4F differentially alters plasma levels of oxidized fatty acids resulting in more anti-inflammatory HDL in mice. Drug Metab Lett. 2010; 4: 139-148.
7. Van Lenten BJ, Wagner AC, Jung CL, Ruchala P, Waring AJ, Lehrer RI, Watson AD, Hama S, Navab M, Anantharamaiah GM, Fogelman AM. Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J Lipid Res. 2008; 49: 2302-2311.
8. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Frank JS, Grijalva VR, Ganesh VK, Mishra VK, Palgunachari MN, Fogelman AM. Oral small peptides render HDL antiinflammatory in mice and monkeys and reduce atherosclerosis in ApoE null mice. Circ Res. 2005; 97: 524-532.
9. Van Lenten BJ, Navab M, Anantharamaiah GM, Buga GM, Reddy ST, Fogelman AM. Multiple indications for anti-inflammatory apolipoprotein mimetic peptides. Curr Opin Investig Drugs. 2008; 9: 1157-1162.
10. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science. 2001; 294: 853-858.
11. Bartel DP MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116: 281-297.
12. Callis TE, Pandya K, Seok HY, Tang RH, Tatsuguchi M, Huang ZP, Chen JF, Deng Z, Gunn B, Shumate J, Willis MS, Selzman CH, Wang DZ. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest. 2009; 119: 2772-2786.
13. Carè A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, Bang ML, Segnalini P, Gu Y, Dalton ND, Elia L, Latronico MV, Høydal M, Autore C, Russo MA, Dorn GW II, Ellingsen O, Ruiz-Lozano P, Peterson KL, Croce CM, Peschle C, Condorelli G. MicroRNA-133 controls cardiac hypertrophy. Nat Med. 2007; 13: 613-618.
14. Joshi SR, McLendon JM, Comer BS, Gerthoffer WT. MicroRNAs: control of essential genes: implications for pulmonary vascular disease. Pulm Circ. 2011; 1: 357-364.
15. Courboulin A, Paulin R, Giguère NJ, Saksouk N, Perreault T, Meloche J, Paquet ER, Biardel S, Provencher S, Côté J, Simard MJ, Bonnet S. Role for miR-204 in human pulmonary arterial hypertension. J Exp Med. 2011; 208: 535-548.
16. Guo L, Qiu Z, Wei L, Yu X, Gao X, Jiang S, Tian H, Jiang C, Zhu D. The microRNA-328 regulates hypoxic pulmonary hypertension by targeting at insulin growth factor 1 receptor and L-type calcium channel-α1C. Hypertension. 2012; 59: 1006-1013.
17. Parikh VN, Jin RC, Rabello S, Gulbahce N, White K, Hale A, Cottrill KA, Shaik RS, Waxman AB, Zhang YY, Maron BA, Hartner JC, Fujiwara Y, Orkin SH, Haley KJ, Barabási AL, Loscalzo J, Chan SY. MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension: results of a network bioinformatics approach. Circulation. 2012; 125: 1520-1532.
18. Renard S, Paulin R, Breuils-Bonnet S, Simard S, Pibarot P, Bonnet S, Provencher S. Pim-1: A new biomarker in pulmonary arterial hypertension. Pulm Circ. 2013; 3: 74-81.
19. Meloche J, Pflieger A, Vaillancourt M, Paulin R, Potus F, Zervopoulos S, Graydon C, Courboulin A, Breuils-Bonnet S, Tremblay E, Couture C, Michelakis ED, Provencher S, Bonnet S. Role for DNA damage signaling in pulmonary arterial hypertension. Circulation. 2014; 129: 786-797.
20. Matori H, Umar S, Nadadur RD, Sharma S, Partow-Navid R, Afkhami M, Amjedi M, Eghbali M. Genistein, a soy phytoestrogen, reverses severe pulmonary hypertension and prevents right heart failure in rats. Hypertension. 2012; 60: 425-430.
21. Umar S, Iorga A, Matori H, Nadadur RD, Li J, Maltese F, van der Laarse A, Eghbali M. Estrogen rescues preexisting severe pulmonary hypertension in rats. Am J Respir Crit Care Med. 2011; 184: 715-723.
22. Myers R. Classical and Modern Regression With Applications. 2nd ed. Boston, MA: PWS-Kent; 1990; chap 7.
23. Umar S, Nadadur RD, Li J, Maltese F, Partownavid P, van der Laarse A, Eghbali M. Intralipid prevents and rescues fatal pulmonary arterial hypertension and right ventricular failure in rats. Hypertension. 2011; 58: 512-518.
24. Tajsic T, Morrell NW. Smooth muscle cell hypertrophy, proliferation, migration and apoptosis in pulmonary hypertension. Compr Physiol. 2011; 1: 295-317.
25. Li Y, Higashi Y, Itabe H, Song YH, Du J, Delafontaine P. Insulin-like growth factor-1 receptor activation inhibits oxidized LDL-induced cyto-chrome C release and apoptosis via the phosphatidylinositol 3 kinase/Akt signaling pathway. Arterioscler Thromb Vasc Biol. 2003; 23: 2178-2184.
26. Niu XL, Li J, Hakim ZS, Rojas M, Runge MS, Madamanchi NR. Leukocyte antigen-related deficiency enhances insulin-like growth factor-1 signaling in vascular smooth muscle cells and promotes neointima formation in response to vascular injury. J Biol Chem. 2007; 282: 19808-19819.
27. Iliopoulos D, Rotem A, Struhl K. Inhibition of miR-193a expression by Max and RXRα activates K-Ras and PLAU to mediate distinct aspects of cellular transformation. Cancer Res. 2011; 71: 5144-5153.
28. Navab M, Reddy ST, Van Lenten BJ, Anantharamaiah GM, Fogelman AM. The role of dysfunctional HDL in atherosclerosis. J Lipid Res. 2009; 50 Suppl: S145-S149.
29. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, Watson AD, Lusis AJ. Atherosclerosis: basic mechanisms: oxidation, inflammation, and genetics. Circulation. 1995; 91: 2488-2496.
30. Sakashita T, Takahashi Y, Kinoshita T, Yoshimoto T. Essential involvement of 12-lipoxygenase in regiospecific andstereospecific oxidation of low density lipoprotein by macrophages. Eur J Biochem. 1999; 265: 825-831.
31. Sigari F, Lee C, Witztum JL, Reaven PD. Fibroblasts that overexpress 15-lipoxygenase generate bioactive and minimally modified LDL. Arterioscler Thromb Vasc Biol. 1997; 17: 3639-3645.
32. Folcik VA, Nivar-Aristy RA, Krajewski LP, Cathcart MK. Lipoxygenase contributes to the oxidation of lipids in human atherosclerotic plaques. J Clin Invest. 1995; 96: 504-510.
33. Kühn H, O'Donnell VB. Inflammation and immune regulation by 12/15-lipoxygenases. Prog Lipid Res. 2006; 45: 334-356.
34. Uderhardt S, Krönke G. 12/15-Lipoxygenase during the regulation of inflammation, immunity, and self-tolerance. J Mol Med (Berl). 2012; 90: 1247-1256.
35. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol. 2011; 8: 222-232.
36. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Fogelman AM. HDL as a biomarker, potential therapeutic target, and therapy. Diabetes. 2009; 58: 2711-2717.
37. Imaizumi S, Navab M, Morgantini C, Charles-Schoeman C, Su F, Gao F, Kwon M, Ganapathy E, Meriwether D, Farias-Eisner R, Fogelman AM, Reddy ST. Dysfunctional high-density lipoprotein and the potential of apolipoprotein A-1 mimetic peptides to normalize the composition and function of lipoproteins. Circ J. 2011; 75: 1533-1538.
38. Navab M, Reddy ST, Anantharamaiah GM, Hough G, Buga GM, Danciger J, Fogelman AM. D-4F-mediated reduction in metabolites of arachidonic and linoleic acids in the small intestine is associated with decreased inflammation in low-density lipoprotein receptor-null mice. J Lipid Res. 2012; 53: 437-445.
39. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, Wagner AC, Frank JS, Datta G, Garber D, Fogelman AM. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation. 2004; 109: 3215-3220.
40. Peterson SJ, Husney D, Kruger AL, Olszanecki R, Ricci F, Rodella LF, Stacchiotti A, Rezzani R, McClung JA, Aronow WS, Ikehara S, Abraham NG. Long-term treatment with the apolipoprotein A1 mimetic peptide increases antioxidants and vascular repair in type I diabetic rats. J Pharmacol Exp Ther. 2007; 322: 514-520.
41. Vecoli C, Cao J, Neglia D, Inoue K, Sodhi K, Vanella L, Gabrielson KK, Bedja D, Paolocci N, L'abbate A, Abraham NG. Apolipoprotein A-I mimetic peptide L-4F prevents myocardial and coronary dysfunction in diabetic mice. J Cell Biochem. 2011; 112: 2616-2626.
42. Peterson SJ, Kim DH, Li M, Positano V, Vanella L, Rodella LF, Piccolomini F, Puri N, Gastaldelli A, Kusmic C, L'Abbate A, Abraham NG. The L-4F mimetic peptide prevents insulin resistance through increased levels of HO-1, pAMPK, and pAKT in obese mice. J Lipid Res. 2009; 50: 1293-1304.
43. Buga GM, Navab M, Imaizumi S, Reddy ST, Yekta B, Hough G, Chanslor S, Anantharamaiah GM, Fogelman AM. L-4F alters hyperlipidemic (but not healthy) mouse plasma to reduce platelet aggregation. Arterioscler Thromb Vasc Biol. 2010; 30: 283-289.
44. Ou J, Ou Z, Jones DW, Holzhauer S, Hatoum OA, Ackerman AW, Weihrauch DW, Gutterman DD, Guice K, Oldham KT, Hillery CA, Pritchard KA Jr L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation. 2003; 107: 2337-2341.
45. Meloche J, Pflieger A, Vaillancourt M, Paulin R, Potus F, Zervopoulos S, Graydon C, Courboulin A, Breuils-Bonnet S, Tremblay E, Couture C, Michelakis ED, Provencher S, Bonnet S. Role for DNA damage signaling in pulmonary arterial hypertension. Circulation. 2014; 129: 786-797.
46. Ma K, He Y, Zhang H, Fei Q, Niu D, Wang D, Ding X, Xu H, Chen X, Zhu J. DNA methylation-regulated miR-193a-3p dictates resistance of hepato-cellular carcinoma to 5-fluorouracil via repression of SRSF2 expression. J Biol Chem. 2012; 287: 5639-5649.
47. Shen J, Liu Z, Todd NW, Zhang H, Liao J, Yu L, Guarnera MA, Li R, Cai L, Zhan M, Jiang F. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer. 2011; 11: 374.
48. Wang S, Xiang J, Li Z, Lu S, Hu J, Gao X, Yu L, Wang L, Wang J, Wu Y, Chen Z, Zhu H. A plasma microRNA panel for early detection of colorec-tal cancer [published online ahead of print March 2, 2013]. Int J Cancer. doi:10.1002/ijc.28136.
49. O'Donnell KA, Wentzel EA, Zeller KI, Dang C V, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature. 2005; 435: 839-843.
50. Wang J, Lu M, Qiu C, Cui Q. TransmiR: a transcription factor-microRNA regulation database. Nucleic Acids Res. 2010; 38(database issue):D119-D122.
51. Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM, Dang CV, Thomas-Tikhonenko A, Mendell JT. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet. 2008; 40: 43-50.
52. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev. 1999; 20: 649-688.
53. Huang JT, Welch JS, Ricote M, Binder CJ, Willson TM, Kelly C, Witztum JL, Funk CD, Conrad D, Glass CK. Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature. 1999; 400: 378-382.
54. Shappell SB, Gupta RA, Manning S, Whitehead R, Boeglin WE, Schneider C, Case T, Price J, Jack GS, Wheeler TM, Matusik RJ, Brash AR, Dubois RN. 15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res. 2001; 61: 497-503.